Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal


           Year.

As part of a broader review of the governance practices of PLx Pharma Inc. (the "Company"), on April 20, 2022, the Board of Directors (the "Board") of the Company amended and restated the Company's Amended and Restated Bylaws (the "Bylaws") to update certain procedures and make various technical and conforming changes. The Bylaws, as amended and restated (the "Amended Bylaws"), were effective immediately and include, among other things, the following changes:

· lowering the ownership threshold for stockholders to call a special meeting

from 66 2/3% to 20%;

· updating the advance notice requirements for director nominations and

shareholder proposals;

· allowing long-term shareholders the ability to nominate directors in the

Company's proxy statement via a "proxy access" provision;

· including a resignation policy for any director who fails to receive support

from a majority of votes cast;

· clarifying the process for stockholders to act by written consent; and

· lowering the threshold for stockholders to amend the Bylaws from a 66 2/3%


   approval to a majority standard.

The Amended Bylaws also contain conforming, clarifying and updating changes, as well as certain other routine and non-substantive updates and revisions. The description above of the Amended Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended Bylaws set forth in Exhibit 3.1 to this Form 8-K and incorporated in this Item by reference.

Item 9.01 Financial Statements and Exhibits.





(d)  Exhibits

     Exhibit No.  Description

     3.1          Amended and Restated Bylaws of PLx Pharma Inc.

     104          Cover Page Interactive Data File (the cover page XBRL tags are
                  embedded within the Inline XBRL document).

© Edgar Online, source Glimpses